| Identification | Back Directory | [Name]
JAK3-IN-1 | [CAS]
1805787-93-2 | [Synonyms]
JAK3-IN-1
JAK3 inhibitor 1
JAK-3-IN-1,JAK3 IN 1,JAK3IN1
2-Propenamide, N-[3-[[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]methyl]phenyl]- | [Molecular Formula]
C26H30ClN7O2 | [MDL Number]
MFCD29472284 | [MOL File]
1805787-93-2.mol | [Molecular Weight]
508.02 |
| Chemical Properties | Back Directory | [density ]
1.315±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 47 mg/mL (92.52 mM) | [form ]
Solid | [pka]
13.48±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
JAK3-IN-1 is a potent, selective and orally active JAK3 inhibitor with an IC50 of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for JAK3 than JAK1 (IC50 of 896 nM) and JAK2 (IC50 of 1050 nM)[1]. | [in vivo]
JAK3-IN-1(Compound 9) shows reasonable pharmacokinetic properties, with moderate T1/2 of 1.4 h, area under the curve (AUC) value of 795 ng*hr/mL following a 10 mg/Kg oral dose and good oral bioavailability of 66%.
After oral administration with JAK3-IN-1(Compound 9) (75 mpk, QD) for 8 days, the numbers of B or T lymphocytes in the tumor-bearing lungs and spleens of treated mice is not affected, however, the number of NK cells is reduced[1]. | [IC 50]
JAK3: 4.8 nM (IC50); JAK1: 896 nM (IC50); JAK2: 1050 nM (IC50); TTK: 49 nM (IC50); BTK: 794 nM (IC50); ITK: 1070 nM (IC50) | [References]
[1] Tan L, et al. Development of Selective Covalent Janus Kinase 3 Inhibitors. J Med Chem. 2015 Aug 27;58(16):6589-6606. DOI:10.1021/acs.jmedchem.5b00710 |
|
|